07.05.2015
- US-based Alexion Pharmaceuticals is paying $8.4 billion to acquire compatriot rare disease specialist Synageva BioPharma. The deal expected to close in mid-2015 has raised...
03.06.2014
- US drugmaker Alexion Pharmaceuticals said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the...
03.01.2013
- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. The following...
